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Background: Our goal was to conduct a systematic review of available randomized controlled trials to compare the safety 
and efficacy of TAVR to SAVR by looking at absolute risk reduction in all-cause mortality for high risk surgical patients 
with severe aortic stenosis at 1, 2 and 5 years post-intervention. 
Methods/Results: The PubMed database was searched according to the PRISMA guidelines from inception until 
September 2020. 6 high quality randomized controlled trials analyzing all-cause mortality for TAVR versus SAVR in the 
CoreValve US High-Risk Clinical Study and Placement of Aortic Transcatheter Valves (PARTNER) Trial populations at 
1, 2 and 5 years post-intervention were included (n = 1,446 participants, randomly assigned to undergo TAVR (738) or 
SAVR (708)). The CoreValve Trial found a statistically significant absolute risk reduction of 4.9% with TAVR compared 
to SAVR at 1 year (superiority P-value of 0.04 and non-inferiority P-value of  <0.001). The Partner Trial also found a 
statistically significant risk reduction of 2.6% with TAVR compared to SAVR at 1 year (non-inferiority P-value of  
<0.001). Additionally, the CoreValve Trial found a statistically significant absolute risk reduction of 6.4% with TAVR 
compared to SAVR at 2 years (superiority P-value of <0.05). The Partner Trial at 2 years and the CoreValve Trial at 5 
years found small, but not statistically significant risk reduction for TAVR compared to SAVR. 
Conclusion: This systematic review showed lower or comparable all-cause mortality rates for TAVR compared to SAVR 
over 2 study populations from large, multicenter randomized controlled trials analyzed at 1, 2, and 5 years intervals, thus 
demonstrating the viability of TAVR for high risk surgical patients with severe AS. Based on these results, as well as the 
additional advantages of TAVR being less invasive, resulting in less acute blood loss, and having a shorter hospital stay 
and recovery time compared to SAVR, healthcare providers should recommend TAVR as a safe and viable alternative to 
SAVR to their patients with severe AS at high surgical risk due to its reduced or comparable all-cause mortality rates up 




Aortic stenosis (AS) occurs when there is a narrowing of the aortic valve opening, usually due to degenerative 
calcification and scarring, impeding the effective passage of blood from the left heart ventricle to the aorta (About the 
Aortic), (Aortic Valve), (Crawford, 2017), (Problem: Aortic, 2016), (Xiushui, 2019). AS leads to reduced cardiac output 
and increased afterload, which overtime cause left ventricular hypertrophy, myocardial dysfunction, arrhythmias, MIs, 
heart failure and sudden cardiac death (About the Aortic), (Aortic Valve), (Otto, 2018), (Papadakis, 2020), (Problem: 
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Aortic, 2016), (Williams, 2016), (Xiushui, 2019). It is estimated that AS affects around 300,000 Americans, including 
12.4% of people over age 75, making it the most common valvular heart disease in the elderly (About the Aortic), (Cover 
Story, 2017), (Nishimura, 2017). AS is the most common valvular disease requiring surgery as well as the most common 
cause of left ventricular outflow obstruction (Otto, 2018), (Papadakis, 2020), (Williams, 2016). It is estimated that aortic 
valve disease costs $10.2 billion in direct costs each year in the US (Moore, 2016).  
There is no effective medical therapy for AS, therefore surgical aortic valve replacement is the only definitive 
treatment for patients with severe AS, which is typically fatal within 2 to 5 years without valve replacement (About the 
Aortic), (Crawford, 2017), (Papadakis, 2020), (Williams, 2017) (Xiushui, 2019). The traditional approach to treating 
severe AS for the past 50 years has been a surgical aortic valve replacement (SAVR), a type of open heart surgery that 
requires the patient be placed on a heart-lung bypass machine (About the Aortic), (Miller, 2016). Transcatheter aortic 
valve replacement (TAVR) is a newer procedure first approved by the FDA in 2011, which provides a less invasive 
alternative to SAVR by using a catheter that is inserted most commonly into the femoral artery and guided to the heart 
using fluoroscopy, when it reaches the aortic valve, a new balloon expandable valve is deployed (About the Aortic). 
While the risks and costs of SAVR and TAVR are similar, the TAVR procedure is less invasive, results in less acute 
blood loss, a shorter hospital stay and recovery time, can be used to repair prosthetic aortic valves that have become 
dysfunctional, and gives patients for whom surgery poses a significant risk or is prohibitive another option (About the 
Aortic), (Crawford, 2017), (Mahmaljy, 2019), (Meduri, 2017), (Miller, 2016), (Papadakis, 2020), (Xiushui, 2019). Up to 
one third of the 300,000 Americans with aortic stenosis are considered too old or too sick to undergo surgery, so TAVR 
provides a crucial, lifesaving option for these patients who previously had no alternative (About the Aortic).  TAVR is 
currently approved by the FDA for patients with severe aortic stenosis at high or intermediate surgical risk. (Cover Story, 
2017), (Xiushui, 2019). The 2017 ACC/AHA guidelines gave a Class 1 recommendation for TAVR for patients with 
severe AS who are high risk surgical patients or patients where the risk of surgery is prohibitive and state that it is also a 
reasonable alternative for intermediate risk surgical patients (STS-PROM 4-8%) (Papadakis, 2020), (Cover Story, 2017), 
(Xiushui, 2019).  
Prior research has found conflicting results on all-cause mortality rates of TAVR compared to SAVR. The 
majority of studies have found significantly lower mortality rates for TAVR compared to SAVR (Adams, 2014), (Deeb, 
2016), (Reardon, 2015), (Smith, 2011). Other studies have found comparable mortality rates (Gleason, 2018), (Kodali, 
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2012) while one study found worse mortality rates (Mack, 2015). In 2016, Siontis et al. published a similar metanalysis 
that looked at the primary outcome of all-cause at 2 years. More research is needed on the durability of TAVR by looking 
at all-cause mortality at 5- and 10-years post-intervention. This research will incorporate more recent studies since the 
publication of this previous metanalysis in 2016 and will also examine all-cause mortality at 5 years, to elucidate a more 
clear picture of mortality rates of TAVR procedure compared to SAVR. 
The purpose of this paper is to conduct a systematic review of published randomized controlled trials (RCTs) 
examining the safety and efficacy of the TAVR and SAVR procedures. We will look at all-cause post-interventional 
mortality rates at 1, 2 and years after TAVR or SAVR in high risk surgical patients with severe AS. This project will 
provide a more definitive conclusion on the mortality rate and durability of TAVR compared to SAVR in order to allow 




Database Search Strategy 
In order to compare all-cause mortality of the TAVR to the SAVR procedure, a systematic review in PubMed was 
conducted using PRISMA guidelines with all available English-language articles through September 2020. We used the 
keywords  “SAVR, TAVR, severe aortic stenosis, high risk surgical patients.” The bibliographies of studies found from 
this search were also reviewed to find additional clinical trials. A further search using the above keywords was conducted 
in Google and Google Scholar to identify grey literature. Initial results were screened by title and abstract and the full-text 
results of all clinical trials were then evaluated by one researcher (EB) to ensure they met inclusion criteria.  
Studies deemed eligible were randomized controlled trials, enrolling men and women, with a study design that 
compared TAVR to SAVR in hig- risk surgical patients with severe aortic stenosis. Included papers had a primary 
outcome of all-cause mortality at 1, 2, or 5 years post-intervention. Excluded trials compared TAVR to medical therapy, 
included low or medium risk surgical patients or patients with moderate aortic stenosis, did not include both sexes, and 
reported only short-term mortality outcomes.  
Data Extraction and Analysis  
Reviewers extracted the data regarding baseline study characteristics (study objectives, study design, length of 
study, year of publication, number of participating centers, number of randomized patients, number of patients assigned to 
each treatment group), baseline patient demographics (sex, age, Society of Thoracic Surgeons Predicted Risk Of Mortality 
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(STS) estimate), quality data and outcomes of interest (absolute risk reduction, superiority or non-inferiority P-values for 
TAVR compared to SAVR). A P-value of <0.05 was considered statistically significant.  
Risk of Bias and Quality Assessment  
The Cochrane Collaboration Tool was used to assess the risk of bias and all studies included were of high quality 
per the 12-question article critique. 
Outcome 
This paper will describe all-cause mortality and absolute risk reduction for TAVR compared to SAVR using 
superiority or non-inferiority P-values at 1, 2 and 5 years post-intervention with the study populations from the CoreValve 




Figure 1: PRISMA flow diagram of literature review and study selection  
 
As demonstrated in Figure 1, the initial keyword search of the PubMed database resulted in 78 articles, which 
were narrowed to 18 studies by including only clinical trials. These 18 studies along with 3 additional studies identified 
through bibliographies were retrieved and reviewed via full-text to ensure they met inclusion criteria. Fifteen studies were 
excluded for various other reasons: 2 did not include both sexes, 10 did not measure the outcome of all-cause mortality, 
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and 3 did not involve high risk surgical patients). Searching reference lists of selected papers and reviews identified 3 
additional studies that met inclusion criteria.  
 All-cause mortality and absolute risk reduction for TAVR versus SAVR at 1, 2 and 5 years post-intervention was 
compared between the CoreValve US High-Risk Clinical Study and Placement of Aortic Transcatheter Valves 
(PARTNER) trial study populations. Table 1 summarizes the characteristics of these trials and their patient populations. 
Both studies were multicenter randomized controlled trials. The CoreValve US High-Risk Clinical Study included 750 
patients from 45 US centers with a mean age of 83 years, 53% males, and a mean STS score of 7.4. Placement of Aortic 
Transcatheter Valves (PARTNER) trial included 699 patients from 25 centers (22 in US, 2 in Canada and 1 in Germany) 
with a mean age of 84 years, 57% males and a mean STS score of 11.7. Patients in the TAVR group of the CoreValve 
study were treated with the CoreValve self-expanding prosthesis (Medtronic Inc). Patients in the PARTNER trial TAVR 
group received the SAPIEN heart-valve system (Edwards Lifesciences). 
 
Table 1 – Characteristics of trials, study populations and interventions of included randomized controlled trials 
 
TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; STS, Society of Thoracic 
Surgeons Predicted Risk of Mortality 
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Table 2 presents the primary outcomes of all-cause mortality at 1, 2, and 5 years of TAVR compared to SAVR for 
the CoreValve and Partner Trail study populations. The CoreValve Trial found a statistically significant absolute risk 
reduction of 4.9% with TAVR compared to SAVR at 1 year (superiority P-value of 0.04 and non-inferiority P-value of  
<0.001). The Partner Trial also found a statistically significant risk reduction of 2.6% with TAVR compared to SAVR at 1 
year (non-inferiority P-value of  <0.001). Additionally, the CoreValve Trial found a statistically significant absolute risk 
reduction of 6.4% with TAVR compared to SAVR at 2 years (superiority P-value of <0.05). The Partner Trial at 2 years 
and the CoreValve Trial at 5 years found small, but not statistically significant risk reduction for TAVR compared to 
SAVR. 
 




TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement 
  
Based on previously referenced Cochrane Collaboration Tool, the risk of bias in all included studies was found to 




In this systematic review examining the results of 6 landmark RCTs, we compared all-cause mortality of TAVR 
to SAVR using between 2 large study populations of high-risk surgical patients with severe AS at 1, 2 and 5 year post-
intervention. The main finding of our comparative efficacy trial was that TAVR had a statistically significant reduction in 
absolute risk or comparable risk at 1 and 2 years compared to SAVR, and comparable mortality in one study and worse 
mortality in another study compared to SAVR at 5 years. Mack et al. was the only included study to find higher all-cause 
mortality rates for TAVR compared to SAVR at 5 years post-intervention. However, sub-group analyses including only 
TAVR patients that underwent a transfemoral approach, excluding patients that underwent a transapical approach, found a 
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63% risk of all-cause mortality at 5 years compared to 64% in the SAVR group (p=0.41) (Mack, 2015). Therefore, we 
have concluded that all-cause mortality for TAVR is reduced or comparable compared to SAVR up to a period of 5 years 
post-intervention for high risk surgical patients with severe AS. Based on these results, as well as the additional 
advantages of TAVR being less invasive, resulting in less acute blood loss, and having a shorter hospital stay and 
recovery time compared to SAVR, healthcare providers should recommend TAVR as a safe and viable alternative to 
SAVR to their patients with severe AS at high surgical risk. If feasible, a trans-femoral approach for TAVR is 
recommended due to lower mortality rates.  
A previous meta-analysis conducted by Siontis et al in 2016, similarly found a 13% relative reduction in all-cause 
mortality at 2 years for TAVR compared to SAVR (hazard ratio (95% CI): 0.87 (0.76–0.99); P = 0.038) in patients with 
severe aortic stenosis at intermediate or high surgical risk. Their subgroup analysis also found reduced mortality for 
TAVR compared to SAVR for patients undergoing a transfemoral access [0.80 (0.69–0.93); P = 0.004], but not 
transthoracic access [1.17 (0.88–1.56); P = 0.293] (Siontis, 2016).   
Limitations for the studies using the CoreValve trial include the learning curve of providers and centers using 
TAVR for the first time compared to SAVR where all surgeons and centers had greater than 5 years’ experience as well as 
their usage of the first generation CoreValve device, which has since been replaced by a third generation device (Adams, 
2014), (Gleason, 2018), (Medtronic CoreValve, 2019), (Reardon, 2015). Limitations for studies using the PARTNER trail 
population include their usage of the first generation Sapien device, which has since been replaced by a fourth generation 
device, the learning curve of providers and centers using TAVR for the first time, and an average STS score of 11.7, 
indicating a very high risk population (Kodali, 2012), (Mack, 2015), (Smith, 2011), (Transcatheter Heart, 2020). 
Furthermore, only 6 RCTs were available for inclusion, limiting the power of this study. Additionally, 10 year post-
interventional data comparing TAVR to SAVR is not yet available.  
More research is needed to evaluate TAVR using the latest generations of the CoreValve (Evolut Pro) and Sapien 
(3 Ultra) devices compared to SAVR and with TAVR procedures performed by experienced surgeons (Medtronic 
CoreValve, 2019), (Transcatheter Heart, 2020). Additional research is also needed on the longer term durability and other 
complications of TAVR compared to SAVR and evaluation of all-cause mortality at 10 years post-intervention. 
In conclusion, this systematic review described  lower or comparable all-cause mortality rates for TAVR 
compared to SAVR over 2 study populations from large, multicenter RCTs analyzed at 1, 2, and 5 years intervals, thus 
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demonstrating the viability of TAVR for high risk surgical patients with severe AS. Based on this research and in 
accordance with existing FDA guidelines, TAVR should be recommended by healthcare providers to their patients with 
severe aortic stenosis and high surgical risk as a viable alternative to SAVR due to its reduced or comparable all-cause 
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